We are international

The IMF is making news all year round.

2016 Press Releases
2015 Press Releases
2014 Press Releases
2013 Press Releases
2012 Press Releases
2011 Press Releases
2010 Press Releases
2009 Press Releases
IMF in the News
Press Release Archive
Bank On A Cure® Press Kit
Media Kit
12.06.13  Latest Myeloma Research, Live IMF Webcasts from American Society of Hematology Meeting

The International Myeloma Foundation says findings to be presented at this year's annual ASH meeting shed new light on when, how long and how much to treat myeloma patients.

–More Than 800 Myeloma Studies Will Be Featured at the 55th Annual Meeting of the American Society of Hematology (ASH)
–The IMF Will Present Several Educational and Informational Programs, and Update the Status of Its Groundbreaking Black Swan Research Initiative® to Find a Cure

12.06.13  The International Myeloma Foundation announces partnership with Onyx Pharmaceuticals to support Black Swan Research Initiative®

- Black Swan Research Initiative (BSRI®) Goal is Improving Treatment Options for Myeloma Patients 

- Onyx Partnership to Support Significant Research Initiative


--The study from the PETHEMA Group in Spain Says an Oral Treatment Regimen “Significantly Delayed Time to Progression” with an Overall Survival Benefit in High-Risk Smoldering Myeloma--


--Study Published in the Prestigious New England Journal of Medicine--

06.27.13  2013 Robert A. Kyle Lifetime Achievement Award Honors Prof. Gösta Gahrton

In Recognition of Significant Contributions to Myeloma Research and Patient Care, the International Myeloma Foundation Honors Dr. Gösta Gahrton with the 2013 Robert A. Kyle Lifetime Achievement Award

06.05.13  The International Myeloma Foundation to Convene First Global Leaders Summit in Stockholm to Raise Disease Awareness and Increase Access to Life-Saving Treatments

Cancer Patient Advocate Leaders from 11 Countries Gather June 13th

Advocate from Turkey Says Patients Are Desperate for Mutual Support

05.31.13  The International Myeloma Foundation Says Positive Recommendation by Regulatory Body Brings Myeloma Patients in Europe Closer to Accessing Latest Treatment

--CHMP Recommendation for Pomalidomide Is Good News for Myeloma Patients in Europe--

--Pomalidomide (POMALYST® in the U.S.) Is an Oral Therapy FDA Approved in the United States for Patients Who Have Had Multiple Prior Treatments--

--The IMF Looks for Other Anti-Myeloma Agents Including KYPROLIS® (Carfilzomib) to Follow--

05.30.13  International Myeloma Foundation Honors Dr. Gösta Gahrton with 2013 Robert A. Kyle Lifetime Achievement Award

In Recognition of Significant Contributions to Myeloma Research and Patient Care

05.02.13  Patients Equal Access Coalition Applauds New Bill to Improve Access to Oral Cancer Drugs
The federal Cancer Drug Coverage Parity Act will dramatically improve the lives of cancer patients. Patients who previously could not afford these treatments will be able to access their life-saving effects. It will also make cancer treatments more practical for patients living in rural and underserved areas by reducing the need to drive long distances for a nurse or doctor to administer treatment.

03.12.13  The International Myeloma Foundation Launches the Black Swan Research Initiative™ to Develop the Very First Definitive Cure for Multiple Myeloma
An entirely new approach to monitoring treatment efficacy to achieve a cure.

02.12.13  Medical Innovation is Helping Patients Live Longer, Better Lives
Newly Approved POMALYST® (Pomalidomide) Is an Oral Therapy with Demonstrated Overall Survival Benefit in Patients Who Have Had Multiple Prior Treatments